Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Lozanski

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
Cancer Immunology Research|March 5, 2015
The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine DevelopmentAlex S Hartlage, Tom Liu, John T Patton, et al.
Mbio|October 5, 2021
Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677HCong Zeng, John P Evans, Julia N Faraone, et al.
The Journal of Clinical Endocrinology and Metabolism|September 9, 2011
Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinomaJaroslaw Jendrzejewski, Jerneja Tomsic, Gerard Lozanski, et al.
Leukemia Research|September 10, 2015
BRAF<sup>V600E</sup> induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activationYo-Ting Tsai, Gerard Lozanski, Amy Lehman, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2022
Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 VariantsPanke Qu, Julia N Faraone, John P Evans, et al.
Plos One|May 11, 2018
Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathologyMuhammad Khalid Khan Niazi, Fazly Salleh Abas, Caglar Senaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapyJohn C Byrd, John G Gribben, Bercedis L Peterson, et al.
Journal of Pathology Informatics|January 7, 2014
Inter-reader variability in follicular lymphoma grading: Conventional and digital readingGerard Lozanski, Michael Pennell, Arwa Shana'ah, et al.
Leukemia|February 11, 2022
Clonal hematopoiesis of indeterminate potential in the companion dogKimberley Sebastian, H Gülçin Özer, Cory Howard, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
Cancer Immunology Research|March 5, 2015
The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine DevelopmentAlex S Hartlage, Tom Liu, John T Patton, et al.
Mbio|October 5, 2021
Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677HCong Zeng, John P Evans, Julia N Faraone, et al.
The Journal of Clinical Endocrinology and Metabolism|September 9, 2011
Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinomaJaroslaw Jendrzejewski, Jerneja Tomsic, Gerard Lozanski, et al.
Leukemia Research|September 10, 2015
BRAF<sup>V600E</sup> induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activationYo-Ting Tsai, Gerard Lozanski, Amy Lehman, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2022
Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 VariantsPanke Qu, Julia N Faraone, John P Evans, et al.
Plos One|May 11, 2018
Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathologyMuhammad Khalid Khan Niazi, Fazly Salleh Abas, Caglar Senaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapyJohn C Byrd, John G Gribben, Bercedis L Peterson, et al.
Journal of Pathology Informatics|January 7, 2014
Inter-reader variability in follicular lymphoma grading: Conventional and digital readingGerard Lozanski, Michael Pennell, Arwa Shana'ah, et al.
Leukemia|February 11, 2022
Clonal hematopoiesis of indeterminate potential in the companion dogKimberley Sebastian, H Gülçin Özer, Cory Howard, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
Pageof 14